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Clinical outcomes following rhythm control for atrial fibrillation: is early better?
Agnieszka Kotalczyka,b, Wern Yew Dinga, Dhiraj Guptaa, David Justin Wrighta and Gregory Y. H. Lipa,b,c
aLiverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK; bDepartment of 
Cardiology, Congenital Heart Diseases and Electrotherapy, Medical University of Silesia, Silesian Centre for Heart Diseases, Zabrze, Poland; cAalborg 
Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
ABSTRACT
Introduction: An integral aspect of atrial fibrillation (AF) management involves better symptom control, 
incorporating a rate control, rhythm control, or a combination strategy. The 2020 ESC Guidelines 
suggest that rhythm control strategy should be recommended for symptomatic patients, to mitigate 
their symptoms and improve the quality of life. However, adequately powered randomized control trials 
and prospective ‘real-world’ registries are needed to fully assess the impact of early rhythm control 
strategies on clinical outcomes in patients with AF.
Objective: In this narrative review, we discuss clinical outcomes following rhythm management 
approach among patients with AF, considering the effectiveness of an early intervention strategy.
Expert opinion: Patients involvement and shared decision-making are crucial when deciding the 
optimal management strategy among patients with AF. For those with newly diagnosed symptomatic 
AF, an early invasive approach such as catheter ablation may have a role in preventing AF progression 
and subsequent pathophysiological changes.
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1. Introduction
Patients with atrial fibrillation (AF) have an increased risk of 
morbidity in terms of ischemic stroke and heart failure, and 
mortality compared to the general population [1]. AF is the 
most common sustained arrhythmia, with a predicted preva-
lence of 17.9 million in European adults by 2060 [2]. A new 
approach, incorporated in the latest 2020 European Society of 
Cardiology (ESC) guidelines on AF [3] – the Atrial fibrillation 
Better Care (ABC) pathway [4], was introduced to improve the 
outcomes of these patients [5,6]. In this pathway, ‘B’ focuses 
on better symptom control in patients with AF by utilizing 
either a rhythm or rate control strategy [4].
In general, a rhythm control strategy is reserved to miti-
gate symptoms and improve the quality of life [3]. 
Nonetheless, among a subset of patients with newly diag-
nosed AF (Table 1), an early intervention approach using 
catheter ablation may prevent further electrical and struc-
tural remodeling associated with disease progression. This is 
important as the restoration of sinus rhythm becomes 
increasingly more challenging with advanced disease states 
[3,7]. In this regard, a rate control strategy has not been 
shown to be beneficial to halt disease progression[6]. 
Therefore, there may be an argument for pursuing 
a rhythm control strategy in the first instance in patients 
with newly diagnosed AF. However, adequately powered 
randomized control trials (RCTs) and prospective ‘real- 
world’ registries are needed to fully assess the impact of 
early vs. late rhythm control strategies on clinical outcomes 
in patients with AF [3].
Due to the complexities of AF and the variety of treatment 
options available [8], adopting a highly individualized 
approach and shared decision-making process are crucial 
when optimizing the treatment of patients with AF (Table 2) 
[3,9,10]. Recently, new tools were developed to further 
improve AF management and research [3,11,12]. The 4S-AF 
scheme (Stroke risk, Symptom severity, Severity of AF burden, 
and Substrate for AF) provides a novel approach toward 
a pathophysiology-based characterization of patients with AF 
[11]. This model is applicable in daily clinical practice to sup-
port decision-making on stroke prevention, choice of rate or 
rhythm control, and management of comorbidities and risk 
factors [3,11]. Quality indicators have also been proposed to 
improve the quality of care in patients with AF [12].
In this narrative review, we provide an overview of the 
rhythm vs rate control strategies, different therapeutic options 
for rhythm control and benefits of an early rhythm control 
approach.
2. Rhythm vs. rate control strategy
Rhythm control in AF involves the restoration of sinus rhythm 
using ablation techniques, cardioversion or long-term treat-
ment with anti-arrhythmic drugs, whereas rate control is 
aimed at allowing AF to persist but with well-controlled ven-
tricular rates (Figure 1)[3,9,10]. In spite of decades of research, 
it has still not been demonstrated conclusively that rhythm 
control strategies are more effective than rate control in 
improving patients’ survival and clinical outcomes [13,14].
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In the AFFIRM study, which was a RCT comparing rhythm 
and rate control strategies among 4060 patients with AF, it 
was found that the rhythm-control strategy offered no survival 
advantage (mortality at five years: 23.8% vs. 21.3% with rate 
control; P = 0.08) and was related to more adverse drug effects 
[15]. The study, published in 2002, predated the advent of 
catheter ablation, and warfarin discontinuation rates were 
particularly high in the rhythm control arm. Indeed, a sub- 
analysis of the trial showed that the presence of sinus rhythm 
and the use of warfarin was associated with a lower risk of 
death [16].
The EORP-AF Pilot Registry was conducted in nine 
European countries to assess contemporary management of 
patients with AF [17]. The influence of a rate vs. rhythm control 
strategy in 3119 real-world patients over a 1-year follow-up 
was reported. It was found that 1036 (33.2%) patients were 
managed with rate control only and 355 (11.4%) patients with 
rhythm control only. The most commonly used drug for rate 
control was beta-blockers, while amiodarone was the most 
frequent anti-arrhythmic drug. Patients assigned to a rhythm 
control strategy were younger and more likely to be male. The 
authors demonstrated that a rhythm control strategy was 
independently related to a lower risk of adverse events and 
all-cause mortality at 1-year follow-up [17]. Likewise, the 
results of Get With The Guidelines-Heart Failure registry 
which included patients with AF and heart failure with pre-
served left ventricular function showed a lower rate of all- 
cause death at one year in the rhythm control group, as 
compared with the rate control group (30.8% vs. 37.5%, 
P < 0.01; HR: 0.86; 95% CI: 0.75–0.98) [18]. A meta-analysis of 
10 RCTs indicated that among young AF patients (aged 
<65 years), rhythm control may be preferable strategy, result-
ing in a higher rate of restoration of sinus rhythm, and a lower 
risk of all-cause mortality and worsening heart failure as com-
pared to rate control strategy [19].
However, an RCT among patients with a recurrence of 
persistent AF showed that rate control was not inferior to 
rhythm control for the prevention of cardiovascular-related 
morbidity and all-cause death [20]. Likewise, the ORBIT-AF 
Registry, consisting of 9749 patients with AF found that 
rhythm control was not superior to rate control strategy, but 
was related to a higher risk of cardiovascular hospitalizations 
(HR: 1.24; 95% CI: 1.10–1.39) [21].
Nonetheless, major limitations of the studies described 
above are that they relied primarily on the use of anti- 
arrhythmic drugs which are known to perform poorly in main-
taining long-term sinus rhythm and are often associated with 
significant side effects. Therefore, it begs the question as to 
whether the results would have been different if we analyzed 
only the subgroup of patients with successful anti-arrhythmic 
treatment or if we utilized a different approach such as AF 
ablation which has been shown to have better success rates 
than drugs.
3. Medical therapy vs. AF ablation
Over the past two decades, the field of AF ablation has 
received much attention. At present, the cornerstone of AF 
catheter ablation is electrical isolation of the pulmonary veins 
(PVI) [22]. This has been associated with good long-term out-
comes in maintaining sinus rhythm with low rates of proce-
dural complications [23,24].
3.1. General AF population
The CABANA trial was a recently published RCT, including 
2204 patients with paroxysmal or persistent AF with 
a median age of 68 years, comparing outcomes of catheter 
ablation vs. antiarrhythmic drug therapy [25]. Patients had 
a median time since AF onset of 1.1 years, and more than 
half the patients had non-paroxysmal AF. Over a median fol-
low-up of 48.5 months, the use of catheter ablation did not 
significantly reduce the combined primary endpoint of death, 
disabling ischemic stroke, major bleeding, or cardiac arrest 
(8.0% vs 9.2%; HR: 0.86; 95% CI: 0.65–1.15). The risk of death 
or cardiovascular hospitalization (HR: 0.83; 95% CI: 0.74–0.93) 
and the risk of AF recurrence (HR: 0.52; 95% CI: 0.45–0.60) was 
Article highlights
● Highly individualized therapy and shared decision-making are crucial 
when deciding the optimal management strategy among patients 
with AF.
● Rhythm control strategy should be considered for symptomatic 
patients, to mitigate the symptoms and improve quality of life.
● Early rhythm control strategy, incorporated into holistic AF care, may 
prevent AF progression and improve outcomes among selected 
patients with newly diagnosed AF.
● Further randomized control trials and ‘real world’ registries are 
needed to assess the impact of early rhythm control strategy on long- 
term clinical outcomes in patients with AF.
Table 2. Factors favoring rate or rhythm control strategies among patients with 
AF [3,6,7].
Rate control Rhythm control
Older age Younger age
Comorbidities Tachycardia-mediated 
cardiomyopathy
Asymptomatic AF Symptomatic AF
Therapy after failure of rhythm 
control
Rate control difficult to achieve
Long standing persistent AF 1st AF episode/Paroxysmal AF
Patient’s preferences
Shared-decision making
AF – atrial fibrillation 
Table 1. Classification of atrial fibrillation [3].
AF type Description
First diagnosed AF ● Not diagnosed before
● Irrespective of AF-duration
Paroxysmal AF ● Episodes terminated spontaneously or with 
intervention <7 days from AF-onset
Persistent AF ● Episodes sustained ≥7 days of AF-onset




● Continuous episode >12 months’ duration, when 
a rhythm control strategy is adapted
Permanent AF ● AF accepted by the patient and physician
● No further attempts to restore/maintain sinus rhythm
AF – atrial fibrillation 
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significantly lower in the ablation group as compared to the 
drug therapy group [25]. However, almost 10% patients ran-
domized to the catheter ablation group did not undergo the 
procedure, whereas 27.5% of patients assigned to the drug 
therapy group received catheter ablation. Such significant 
cross-over may have introduced bias to the results and in 
fact, the ‘as-treated’ analysis demonstrated catheter ablation 
to be superior to medical therapy. Indeed, a subsequent ‘real- 
world’ study revealed that catheter ablation was related to 
a reduction in the composite endpoint of death, disabling 
ischemic stroke, major bleeding, or cardiac arrest (HR: 0.75; 
95% CI: 0.70–0.81); and that the benefit was more significant 
in the CABANA-eligible patients (HR 0.70, 95% CI 0.63–0.77) 
compared with the medical therapy group [26].
Notably, a meta-analysis of nine studies assessed the 
long-term outcomes of catheter ablation vs. medical therapy 
alone in a general AF population (n = 241,372) [27]. During 
a follow-up of 3.5 years, catheter ablation significantly 
reduced the risk of death (HR: 0.62; 95% CI: 0.54-0.72), 
stroke (HR: 0.63; 95% CI: 0.56-0.70), and hospitalization 
(HR: 0.64; 95% CI: 0.51-0.80) as compared to the medical 
therapy [27].
Likewise, a study of 2,720 patients with AF who underwent 
an ablation assessed the impact of the procedure on recurrent 
hospitalizations [28]. AF ablation was related to a 35% decline 
in all-cause hospitalizations (from 1,669 hospitalizations in 
the year pre-ablation to 1,034 hospitalizations in the year post- 
ablation), which was driven by a reduction in hospitalizations 
for AF and heart failure (a reduction of 56% and 43%, respec-
tively) [28]. The independent predictors for decreased AF hos-
pitalization were age <55 years, history of obstructive sleep 
apnea and heart failure [28]. Furthermore, catheter ablation 
significantly increased the time to first recurrence of atrial 
arrhythmias among patients with paroxysmal and persistent 
AF, during the 12-year follow-up period in comparison to anti- 
arrhythmic drugs [29].




































Figure 1. General management strategy among patients with atrial fibrillation AV – atrioventricular; AF – atrial fibrillation; NDCC – Non-dihydropyridine calcium 
channel blocker; AAD – antiarrhythmic drug; RV – right ventricular; BIV – biventricular. Based on Refs [3,4,9,10].
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Another study assessed the risk of ischemic stroke and intra-
cranial hemorrhage among patients with AF, depending on the 
treatment strategy [30]. At 51 months of follow-up, 35.8% of 
patients with catheter ablation had an AF recurrence, and 29.7% 
of these patients underwent a repeat procedure. It was found 
that the risk of ischemic stroke was significantly higher in the 
group treated with medical therapy as compared to the catheter 
ablation group and the non-AF group (Incidence Rate Ratio [IRR]: 
1.09% vs 0.30% vs 0.34%; respectively). Of note, among those 
remaining in sinus rhythm after ablation, the risk of stroke was 
lower than in patients with post-ablation AF recurrences (IRR: 
0.87% vs 0.24%). Curiously, the authors reported that the risk of 
intracranial bleeding was lower in the ablation group than in the 
medical therapy group (IRR: 0.06% vs. 0.17%); and that the risk of 
intracranial bleeding did not differ between the ablation group 
and the non-AF group [30]. In this regard, it seems implausible 
that catheter AF ablation would directly influence the risk of ICH, 
suggesting that there may be potential bias in the study [31]. 
A separate analysis using the same database of patients with AF 
showed that catheter ablation was related to a lower incidence 
and risk of dementia, including Alzheimer’s disease and vascular 
dementia (HR: 0.73; 95% CI: 0.58–0.93) compared with patients 
with medical therapy during a follow-up of 52 months [32].
3.2. Patients with atrial fibrillation and heart failure
CASTLE-AF was an RCT assessing the outcomes among 
patients with symptomatic paroxysmal or persistent AF and 
symptomatic heart failure (left ventricular ejection fraction 
≤35%) with an implanted cardioverter-defibrillator, and 
a history of unsuccessful [or unwillingness to take] antiarrhyth-
mic drug therapy [33]. Patients were randomized to catheter 
ablation or standard medical therapy. A significantly lower rate 
of a composite endpoint of all-cause death or hospitalization 
for worsening heart failure was observed among those in the 
ablation group as compared to the drug therapy group (28.5% 
vs 44.6%; HR: 0.62; 95% CI: 0.43–0.87); catheter ablation was 
also related to a lower burden of AF, increased the 6-min 
walking distance, and improved the left ventricular ejection 
fraction [33]. However, only a minority of patients who were 
initially screened for the trial were found to be eligible. 
Indeed, a study [34] assessing the generalizability of CASTLE- 
AF showed that only 7.8% of patients in routine practice 
would have met the inclusion criteria for the CASTLE-AF. 
Nonetheless, this study found that patients in the catheter 
ablation group had a lower risk of the primary outcome as 
compared to standard medical therapy (HR: 0.81; 95% CI: 
0.76–0.87) [34].
A meta-analysis of seven RCTs among patients with AF 
and heart failure showed that catheter ablation was asso-
ciated with a significant reduction in mortality (risk ratio 
[RR]: 0.50; 95% CI: 0.34–0.74) and hospitalizations for heart 
failure (RR: 0.56; 95% CI: 0.44–0.71); and led to improve-
ments in left ventricular ejection fraction (weighted mean 
difference: 7.48; 95% CI: 3.71–11.26) as compared to medical 
therapy [35]. Nonetheless, it is important to note that the 
inclusion and exclusion criteria differed between the ana-
lyzed studies.
Overall, a rhythm control strategy with anti-arrhythmic 
drugs is not superior to rate control in terms of mortality 
and clinical outcomes [15]. However, catheter AF ablation 
may have a positive effect on all-cause mortality, risk of stroke, 
re-hospitalization, cognitive function, and quality of life 
among patients with paroxysmal and persistent AF as com-
pared to medical therapy, especially in specific subgroups 
[29,30,32,36]. Patients with ‘long-standing persistent’ AF 
(>3 years continuously in AF prior to ablation) are less likely 
to restore and maintain the sinus rhythm post ablation than 
Table 3. The AFFIRM trial vs. the EAST-AFNET 4 trial.
AFFIRM [15] EAST-AFNET 4 [43]
Era when patients were 
recruited
1995–2002 2011–2016
Mean age of patients [years] 69.7 ± 9.0 70.2 ± 8.4
Absence of symptoms (%) 6 30
Mean Time since AF diagnosis 
[days]
42 36
Mean Left atrial size (cm) 4.3 ± 0.8 4.4 ± 0.9
Composite primary end point All-cause death Death from cardiovascular  
causes, stroke, or  
hospitalization with  
worsening of heart failure or acute  
coronary syndrome
OAC discontinuation rates [%] 15 3.2
SR maintenance rates in 
rhythm arm [%]
62.6 82.1
Ablation utilization [%] 0.7 19.4
Structured follow up [years] 3.5 5.1
AF – atrial fibrillation; OAC – oral anticoagulant; SR – sinus rhythm 
Table 4. Factors adversely affecting outcomes of catheter ablation [3,58–63].
Factors adversely affecting outcomes osf catheter ablation
-Non-paroxysmal AF 
-AF duration > 6 years 
-Age > 75 years 
-Female sex 
-Left atrial volume indexed to body surface area >34 ml/m2 
-Atrial dilatation > 50 mm 
-Structural heart disease 
-Obesity 
-Sleep apnea 
-Chronic kidney disease (GFR <60 ml/min/1.73 m2)
AF – atrial fibrillation; GFR – glomerular filtration rate 
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those with paroxysmal AF [37]. Of note, time since the first AF 
episode and heart failure are associated with higher, whereas 
the absence of structural heart disease, with lower AF recur-
rences after catheter ablation [38]. A 10-year post AF ablation 
follow-up of 255 patients showed that greater LA anteropos-
terior diameter, hypertension, higher BMI and increased fast-
ing blood glucose were independently associated with AF 
recurrences [39].
Given the current literature, patient selection, and prefer-
ences are important aspects of treatment, including the ben-
efit-risk assessment of ablation in order to identify an optimal 
individualized strategy [40]. Further studies are needed to 
determine whether there are additional subgroups who may 
benefit from AF ablation in terms of reducing long-term com-
plications and improving survival.
4. Early rhythm control
Early intervention in the ‘natural history’ of AF may prevent its 
progression and AF-related pathophysiological changes [41]. 
New management strategies are proposed to maintain sinus 
rhythm in the ‘early-stage’ AF and improve clinical outcomes 
in patients with AF [42].
The recently published EAST-AFNET 4 trial included 2789 
patients with AF diagnosed up to one year prior to enrollment; 
which was symptomatic in around 70% of patients [43]. 
Patients were randomized to early rhythm control (treatment 
with antiarrhythmic drugs or AF ablation) or usual care 
(rhythm control was limited to the symptomatic patients). 
The primary composite outcome was cardiovascular-related 
death, stroke, or cardiovascular-related hospitalization; and 
the primary composite safety outcome was death, stroke, or 
serious adverse events related to rhythm control therapy. The 
trial was discontinued after a median of 5.1 years of follow-up 
due to the demonstration at the third interim analysis that 
early rhythm control therapy was related to a lower risk of 
adverse cardiovascular outcomes than usual care. The first- 
primary-outcome event rate was 3.9 per 100 person-years in 
the early rhythm control group vs 5.0 per 100 person-years in 
the usual care group (HR: 0.79; 96% CI: 0.66–0.94), while the 
primary safety outcome did not differ significantly between 
the groups. The use of oral anticoagulation (OAC) was con-
tinued during the follow-up (although data on quality of antic-
oagulation were not reported), and the incidence of ischemic 
stroke was low in both groups (0.6% in the early rhythm 
control group and 0.9% in the usual care group). Of note, 
sinus rhythm at 24 months was maintained in 82% of the 
patients assigned to early rhythm control and 60% of patients 
in the usual care group [43]. It is important to note that only 
around one in five patients in the rhythm control arm under-
went catheter ablation during the study period, with antiar-
rhythmic drugs being the predominant mode of rhythm 
control. 14.6% of patients in the usual care group too received 
the rhythm control therapy to mitigate their symptoms. Given 
that patients in the early rhythm control group underwent an 
intense, structured follow-up, the positive results may have 
been influenced by better treatment of risk factor and comor-
bidities in the intervention arm [44]. As shown in Table 3, there 
are important differences between the AFFIRM and EAST- 
AFNET4 trials, which may explain the different headline results. 
In particular, the success rate of the rhythm control strategy 
was significantly higher in EAST-AFNET4, and the OAC discon-
tinuation rates significantly lower than in AFFIRM. In summary, 
EAST-AFNET four suggests that early rhythm control is 
a reasonable consideration as part of a holistic approach to 
AF care [3,45].
A decade ago, the MANTRA-PAF study [46] was performed 
to evaluate the outcomes of radiofrequency ablation as first- 
line therapy for patients with paroxysmal AF. Patients were 
randomized to receive radiofrequency catheter ablation or 
treatment with anti-arrhythmic drugs. Primary end points 
were the cumulative and per-visit burden of AF assessed in 
7-day Holter-ECG (at 3, 6, 12, 18, and 24 months). Although 
there was no significant difference between groups in the 
cumulative burden of AF, the AF burden at 24 months, was 
significantly lower in the ablation group than in the AAD 
group (9% vs. 18%; P = 0.007); and more patients in the 
ablation group were free from symptomatic AF (93% vs. 
84%; P = 0.01) [46].
Results of two RCTs, evaluating cryoballoon AF ablation as 
a first-line strategy compared with anti-arrhythmic drug ther-
apy: the STOP-AF FIRST [47] and the EARLY-AF [48] have been 
recently published. The trials comprised of patients with 
symptomatic, paroxysmal AF untreated previously with 
rhythm-control strategy, and without severe left atrial enlarge-
ment (diameter <5 cm) [47,48]. Both studies showed that 
cryoballoon ablation had a superior efficacy as first-line ther-
apy as compared to antiarrhythmic drugs (class I or III agents) 
during 12 months of follow-up [47,48]. The primary efficacy 
outcome of the STOP-AF FIRST was defined as the freedom 
from efficacy failure, i.e, acute procedural failure, any subse-
quent AF surgery or ablation, atrial arrhythmias or cardiover-
sion (and antiarrhythmic drug therapy in the ablation group) 
after the 90-day blanking period [47]. It occurred in 75% of 
patients from the cryoballoon ablation group and in 45% of 
those from the antiarrhythmic drug therapy group [47]. 
Limitations of the study include arrhythmia assessment with 
intermittent electrocardiography monitoring, possibly inade-
quate drug dosing in the drug therapy arm (the drug failures 
were observed mostly among patients taking very low doses), 
and a 15% rate of crossover from drug therapy arm to the 
ablation group which counted as a component of the primary 
efficacy outcome [47]. On the other hand, EARLY-AF study was 
methodologically more sound, in that there was no crossover 
from the drug therapy to the ablation group, and there was 
continuous rhythm monitoring with an implantable loop 
recorder. As such, the results of EARLY-AF study [48] may be 
more representative of the true benefits of catheter ablation: 
atrial tachyarrhythmia occurred in 43% of patients in the 
ablation group and in 68% of those from the antiarrhythmic 
drug therapy (HR: 0.48; 95% CI: 0.35–0.66). 11% of patients in 
the ablation arm had symptomatic post-ablation atrial tachyar-
rhythmia vs. 26.2% of those from the antiarrhythmic drug 
therapy (HR: 0.39; 95% CI: 0.22–0.68), and this was associated 
with better QOL improvements and lower incidence of hospi-
talization on follow up [48].
The recently presented Cryo-FIRST Cryoballoon Ablation 
Trial (NCT01803438) [49] among naïve patients with AF 
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similarly showed a higher arrhythmia-free survival rate among 
patients after cryoballoon ablation as compared to the anti- 
arrhythmic drugs therapy group (82.2% vs. 67.6%) during 
12 months of follow-up [50]. In addition, an improvement in 
the quality of life was observed in the catheter ablation group; 
and 86.5% of the these patients were symptom-free vs. 70.4% 
of patients in the anti-arrhythmic drug group [51]. Of note, the 
results of ATTEST trial [52] support the notion of increased 
benefit with AF catheter ablation as compared to AAD ther-
apy. The study assessed the AF progression among patients 
with paroxysmal AF, randomized to radiofrequency ablation or 
AAD treatment. At 3 years, the rate of persistent AF/atrial 
tachycardia was significantly lower in the ablation group com-
pared with the AAD therapy group (2.4% vs. 17.5%; 
P = 0.0009). It was found that patients aged ≥65 years were 
more likely to progress to persistent arrhythmia than those 
aged <65 years (HR: 3.87; 95% CI: 0.88–17.00) [52].
A recent European multicentre registry [53] showed that 
cryoballoon ablation may be useful as a first-line option even 
for patients with persistent AF. At 24 months, the arrhythmia- 
free survival rate was 64% of patients with persistent AF and 
57% of those with long-standing persistent AF. Repeat proce-
dures were required in 20% of those with persistent AF and in 
32% of subjects with long-standing persistent AF.
A study [54] among 1241 patients showed that the time 
interval between AF diagnosis and ablation was associated 
with procedural outcomes. It found that the shorter diagnosis- 
to-ablation time of less than 1 year was related to a lower rate 
of AF recurrence, and a reduction in atrial remodeling biomar-
kers, i.e. B-type natriuretic peptide, C-reactive protein, and left 
atrial size as compared to those with the longer diagnosis-to- 
ablation time [54]. Thus, early ablation-based rhythm control 
may prevent cardiac remodeling, thereby translating to phy-
siological and symptomatic improvement, in particular among 
patients with AF and tachycardia-mediated cardiomyopa-
thy [55].
Given the significant upfront costs of catheter ablation, the 
cost-effectiveness of using it as first-line therapy needs to be 
evaluated. A subanalysis [56] of the MANTRA-PAF trial was 
performed to estimate the cost-effectiveness of radiofre-
quency catheter ablation for paroxysmal AF as first-line treat-
ment, compared with antiarrhythmic drugs during the 2-year 
follow-up. Radiofrequency catheter ablation was found to be 
a cost-effective strategy in younger patients (€3434/quality- 
adjusted life years [QALY] in ≤50-year-old patients vs. €108 
937/QALY in >50-year-old patients) [56]. It should be noted 
that in the MANTRA-PAF trial, almost half the patients in the 
ablation arm required repeat procedures, whereas the corre-
sponding figure in the recent cryoballoon trials was around 1 
in 10. This, along with the much shorter procedure times with 
Cryoballoon as compared to radiofrequency ablation [57], 
means that cost-effectiveness of cryoballoon PVI as first-line 
treatment can be expected to be even higher.
The use of an early rhythm control strategy may reduce AF- 
related adverse clinical outcomes among patients with 
recently diagnosed AF. For this purpose, catheter ablation as 
first-line treatment may be a safe and effective approach, with 
superior results compared to anti-arrhythmic drugs. However, 
the long-term impact on heart failure and mortality has not 
been studied; and prognostic implications of this strategy 
require further confirmation in RCTs and ‘real-world’ studies.
5. Factors adversely affecting outcomes of catheter 
ablation
Several scores, stratifying the risk of adverse outcomes or AF 
recurrence among patients undergoing AF catheter ablation, 
have been developed. (Table 4) [3,58–60]. The validity of these 
scores requires further confirmation in large cohort studies; 
and the use of biomarkers or cardiovascular imaging may 
improve their predictive value. Besides the evaluation of the 
predictors of AF recurrence, the personalized approach, 
including the patient’s preferences, should be adjusted [3,61].
Left atrial volume was shown to be the most important 
independent predictor of AF recurrence post-ablation [62]. 
A pooled meta-analysis of 7217 patients who underwent AF 
ablation showed a 31.2% AF recurrence rate during a follow- 
up of 22 months [63]. Patients with persistent AF had a greater 
risk of arrhythmia recurrence after the first ablation (OR 1.78; 
99% CI: 1.14–2.77) than these with paroxysmal AF. In the 
overall population, the strongest predictors of AF ablation 
failure were an early (>30 days) AF recurrence (OR: 4.30; 95% 
CI: 2.00–10.80), a left atrial diameter >50 mm (OR: 5.10; 95% CI: 
2.00–12.90), and valvular AF (OR: 5.20; 95% CI: 2.22–9.50) [63].
6. Conclusions
The management of AF should be individualized with a shared 
decision-making process in order to determine the optimal 
rhythm or rate control strategy to pursue. The benefit of anti- 
arrhythmic drugs compared to rate control options remains 
unproven. However, there is emerging evidence that catheter 
AF ablation may be more effective than rate control alone in 
improving the patients’ QOL, and clinical outcomes. As such, an 
early rhythm control strategy using catheter ablation may be 
a promising approach among patients with newly diagnosed 
paroxysmal AF when recommended as part of holistic care.
7. Expert opinion on the future of AF management
Rhythm control involves AF ablation, cardioversion or long- 
term treatment with anti-arrhythmic drugs to maintain sinus 
rhythm; which should be recommended for symptom relief 
and to improve quality of life(3).
Historically, acute peri-procedural complications occurred 
in 4.8–7.8% of patients undergoing AF ablation, including 
tamponade, stroke, or transient ischemic attack, and death 
(<0.1%) [25,64–66]. During long-term follow-up, re-ablation 
was required in 20–50% of patients [67,68]. However, more 
recent studies have not only shown a much lower risk of major 
complications (<2%), but also a significantly lower need for 
repeat procedures (<20%) [25,47,48]. Also, a small subset of 
patients with persistent and long-standing AF may benefit 
from a hybrid approach, integrating the strengths of both 
surgical and catheter ablation [69,70]. There are also limited 
data regarding AF ablation and left atrial appendage occlusion 
performed as a single procedure; to integrate the ‘cure’ for AF 
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and prevent stroke complications, in order to avoid the risk 
associated with repeated procedures [71–73].
Given the current evidence-base, rhythm control may be 
the preferred option among patients with AF and acute heart 
failure; and for unstable patients, an urgent cardioversion 
should be considered [74]. In this setting, all anti-arrhythmic 
agents apart from amiodarone, are contraindicated. Therefore, 
electrical cardioversion should be considered as it restores 
sinus rhythm faster and also more effectively than pharmaco-
logical cardioversion with amiodarone [74]. It is important that 
thromboembolic risk should be assessed and an OAC initiated 
prior to the procedure. In those at increased risk of stroke, the 
OAC should be continued lifelong [75]. A study among 5625 
patients with AF and acute heart failure showed that success-
ful restoration of sinus rhythm was related to a significantly 
lower rate of all-cause mortality (HR: 0.68; 95% CI: 0.49–0.93), 
heart failure re-hospitalization (HR: 0.66; 95% CI: 0.45–0.97) as 
compared to persistent AF, during 2.6 years of follow-up [76]. 
Notably, most patients with recent-onset AF will convert spon-
taneously within 48 hours, and a wait-and-see approach may 
be reasonable in stable patients [75,77].
First and foremost, it is crucial to assess and treat comor-
bidities. A position paper on the prevention of AF highlighted 
that avoidable or modifiable risk factors are related to lifestyle 
choices, e.g. diet modification, quitting smoking and alcohol, 
regular physical activity [78]. Hence, as clinicians, we should 
direct our focus toward specific at-risk groups such as adoles-
cents who, paradoxically, are at increased cardiac risk due to 
the epidemics of obesity, inadequate nutrition, smoking and 
alcohol abuse [78,79]. Of note, obesity [and male gender] were 
independent predictors of failed cardioversion [80], whereas 
weight-loss was related to the maintenance of sinus rhythm 
[81]. Likewise, the RACE 3 was a RCT of 245 patients with early 
persistent AF and mild-to-moderate heart failure randomized 
to the targeted therapy of underlying conditions or conven-
tional therapy [82]. Both groups received standard treatment 
of AF and heart failure, and rhythm control therapy. At one- 
year follow-up, the improvement in blood pressure, lipid pro-
file, weight and heart failure was observed in the intervention 
group. Besides, sinus rhythm was present in 75% of patients 
with targeted therapy vs. 63% in the conventional group (odds 
ratio [OR]: 1.76; 95% CI: 1.02–3.05) [82].
Likewise, impressive progress in the field of the electrophy-
siology has led to improvements of existing techniques and 
tools, and new ones are constantly emerging, increasing the 
efficacy and safety of catheter AF ablation [83,84]. Of note, the 
randomized trials (e.g. CIRCA-DOSE, FIRE and ICE) directly 
comparing cryoballoon vs. radiofrequency ablation did not 
find one energy source superior to the other [85,86]. In addi-
tion, point-by-point radiofrequency ablation developed signif-
icantly during last decade (introduction of contact force 
catheters, ablation indexes). It is expected that single-shot 
PVI ablation will enable quicker and more durable ablation 
lesion sets [84,87]. Moreover, advances in electroanatomical 
mapping technologies have provided a better understanding 
of the triggers for AF, outside of the pulmonary veins [88]. 
With the integration of these AF mapping systems, specific 
targets for ablation may be identified, resulting in better AF 
control beyond PVI alone [84,89]. More recently, the most 
promising new technology in catheter AF ablation is pulsed- 
field ablation (PFA) [90]. This technique is used to create 
micropores at the cell membranes to ablate myocardium with-
out tissue heating [91]. The IMPULSE (NCT03700385) and the 
PEFCAT (NCT03714178) were the first human trials on PFA, 
presenting excellent efficacy and safety data. PFA was 
reported to be an ‘ultrafast’ procedure with a 100% efficacy 
in terms of 3-month durability of PVI [92]. Additionally, early 
studies with electroporation show very promising high success 
rate and low complication rate. Thus, catheter ablation is 
a procedure that comprises different approaches, which are 
continuously evolving.
Complementary data on the identification and monitoring 
of AF can be seen in the use wearable technology and implan-
table loop recorders to detect and record AF episodes [93–97]. 
Indeed, smartwatches may be used for long-term AF screening 
in large populations, especially in high-risk patients. Early AF 
detection and implementation of proper therapy may reduce 
the risk of AF-related complications [98]. A recent study 
showed that patients with pre-ablation AF episodes lasting 
less than 24 hours (continuously) had a significantly lower 
incidence of arrhythmia recurrence following AF ablation com-
pared to those with AF pre-ablation episodes of between two 
and seven days, and those with episodes for more than seven 
days (0% vs. 0.1% vs. 1.0%; respectively) [99]. Thus, wearable 
technology may be a useful tool to assess the burden of AF for 
risk stratification pre-ablation. Furthermore, it can be used to 
monitor for AF recurrences during long-term follow-up. 
Regular post-ablation follow-up is crucial to implement appro-
priate and effective rhythm control therapy, assess symptoms, 
and detect and optimize treatment of concomitant risk factors 
and comorbidities [98,100–105]. Overall, the wearable technol-
ogy may assist in integrated care, optimizing the holistic 
approach among patients with AF [106].
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